Target intelligence / Profile preview

Membrane-spanning 4-domains subfamily A member 6A (MS4A6A)

Target
MS4A6A
Molecular classification
Four-span transmembrane protein, Membrane protein, Component of multimeric receptor complex, Other
01

Overview

MS4A6A (Membrane-spanning 4-domains subfamily A member 6A) is a member of the MS4A gene family, defined by four transmembrane domains, and is primarily expressed in microglia in the brain. It acts as a regulator of microglial immune function, participates in signal transduction within multimeric receptor complexes, and modulates inflammatory responses. MS4A6A genetic variants are implicated in the risk for Alzheimer’s disease and other neurodegenerative disorders through their influence on amyloid-beta clearance and inflammatory pathways. While no drugs currently target MS4A6A directly, understanding its biology supports ongoing research into microglia and neurodegenerative disease therapy.

Other names
Membrane-spanning 4-domains subfamily A member 6AMS4A6A4SPAN3CD20L3MS4A6CDA01MSTP090Four-span transmembrane protein 3CD20 antigen-like 34SPAN3.14SPAN3.2membrane-spanning 4-domains subfamily A member 6ACD20-like precursorHAIRB-isoMS4A6A-polymorphMST090
02

Mechanism of action

For potential modulators: Regulation of microglia activation, inflammation suppression (JAK2/NF-κB signaling), and enhancement of amyloid-beta phagocytosis. Targeting transcription/expression levels via SNPs that modulate MS4A6A abundance, which correlates to AD risk and biomarker changes.

03

Biological functions

Signal transduction as part of receptor complexesMicroglial immune function and regulationSuppression of microglial inflammationAmyloid-beta clearance in the brain
04

Disease associations

Alzheimer’s disease (modulates risk and amyloid-beta clearance)Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathyFrontotemporal dementia and/or amyotrophic lateral sclerosis
05

Safety considerations

No direct safety concerns identified; unknown effects of direct modulation due to lack of available drugs.Therapeutic targeting could affect microglial immune responses and neuroinflammation, with theoretical risks of exacerbating or suppressing central nervous system inflammation.
06

Interacting drugs

No approved drugs directly targeting MS4A6A are currently listed in curated databases or recent literature. Research is ongoing in context of neurodegenerative disease modulation and microglial biology.
07

Biomarkers

CSF Aβ42 levels (affected by MS4A6A SNPs, reflecting amyloid pathology in AD)Soluble TREM2 (occasionally correlated with specific MS4A6A SNPs)

Beyond the preview

Go deeper on Membrane-spanning 4-domains subfamily A member 6A (MS4A6A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Membrane-spanning 4-domains subfamily A member 6A (MS4A6A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call